Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy

US8101359B2 · kind B2 · utility

Assignee

• EPIGENOMICS AG · DE

Inventors

• John Foekens · Capelle aan den IJssel, NL
• Nadia Harbeck · Otterfing, DE
• Thomas Koenig · Berlin, DE
• Sabine Maier · Brussels, BE
• John W. Martens · Rotterdam, NL
• Fabian Model · Berlin, DE
• Inko Nimmrich · Berlin, DE
• Tamas Rujan · Oberwil, CH
• Armin Schmitt · Berlin, DE
• Manfred Schmitt · Munich, DE
• Maxime P. Look · Amsterdam, NL
• Almuth Marx · Nuremberg, DE
• Heinz Hoefler · Munich, DE

Key dates

• Filing date: Oct 1, 2003
• Grant date: Jan 24, 2012
• Expiry date: Mar 11, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/16
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.